Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Yu on Combination Therapy for Patients With Metastatic Prostate Cancer

February 14th 2019

Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses combination therapy for patients with newly diagnosed metastatic prostate cancer.

Long-Term Evidence Supports Use of SBRT in Prostate Cancer

February 14th 2019

Stereotactic body radiation therapy has been found to be a safe and effective option for patients with low- and intermediate-risk prostate cancer.

Hormonal Agents Induce Improved OS in African Americans With Chemo-Naive mCRPC

February 12th 2019

African-American men with metastatic castration-resistant prostate cancer treated with novel hormonal therapies—namely abiraterone acetate or enzalutamide—lived 20% longer than their Caucasian counterparts.

Dr. Dorff on Sequencing in Metastatic Castration-Resistant Prostate Cancer

February 12th 2019

Tanya B. Dorff, MD, associate clinical professor in the Department of Medical Oncology and Therapeutics Research, and head of the genitourinary cancers program at City of Hope, discusses sequencing in metastatic castration-resistant prostate cancer (mCRPC).

LuPSMA May Improve Survival in Heavily Pretreated mCRPC

February 12th 2019

The novel targeted radiation therapy lutetium-177 PSMA-617 showed strong clinical activity and the potential to improve survival in heavily pretreated men with PSMA-positive metastatic castration-resistant prostate cancer.

Dr. Rayford on Improving Stratification of Patients With Prostate Cancer

February 9th 2019

Walter Rayford, MD, PhD, MBA, a urologic oncologist with the Urology Group and associate professor of medicine at the University of Tennessee West Cancer Center, discusses ways to improve stratification of patients with prostate cancer.

Is the Sipuleucel-T Saga Poised for a New Chapter?

February 6th 2019

Advocates for sipuleucel-T point out that the public has become more aware of and interested in immunotherapy now, and they believe the product has the potential to benefit a larger group of patients.

Dr. Gieschen on Standard Approaches to Radiation Therapy in Prostate Cancer

February 5th 2019

Holger L. Gieschen, MD, assistant professor, University of Tennessee Health Science Center, radiation oncologist, West Cancer Center, discusses standard approaches to radiation therapy in prostate cancer.

Identifying Factors That Limit Access to Prostate Cancer Therapy

February 2nd 2019

Jay H. Fowke, PhD, MPH, MS, chief, Division of Epidemiology, professor of preventive medicine, University of Tennessee Health Science Center, discusses factors that can lead to disparity in access to prostate cancer therapy.

Dr. Burgess on Understanding Molecular Subtypes of Prostate Cancer

January 31st 2019

Earle Burgess, MD, associate professor of medicine, Levine Cancer Institute, Atrium Health, discusses the importance of understanding the molecular subtypes of prostate cancer.

Apalutamide Improves Survival in Metastatic Castration-Sensitive Prostate Cancer

January 31st 2019

Apalutamide (Erleada) in combination with androgen deprivation therapy was found to significantly improve radiographic progression-free survival and overall survival versus placebo in patients with metastatic castration-sensitive prostate cancer.

Advancements Emerging in Nonmetastatic and mCRPC Paradigms

January 25th 2019

Tanya B. Dorff, MD, discusses landmark approvals in nonmetastatic castration-resistant prostate cancer and anticipated developments in the space.

Dr. Dorff on Choosing Between Therapies in Nonmetastatic CRPC

January 24th 2019

Tanya B. Dorff, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, head, Genitourinary Cancers Program, City of Hope, discusses choosing between therapies in nonmetastatic castration-resistant prostate cancer.

Dr. Rayford on Racial Risk Stratification in Prostate Cancer

January 16th 2019

Walter Rayford, MD, PhD, MBA, a urologic oncologist with the Urology Group and associate professor of medicine at the University of Tennessee West Cancer Center, discusses a study aiming to refine racial risk stratification in prostate cancer.

Yu Previews Future of Castration-Naive Prostate Cancer

January 14th 2019

Evan Y. Yu, MD, discusses the available options for patients with metastatic castration-naïve prostate cancer.

Few Unanswered Questions Remain for Nonmetastatic Prostate Cancer

January 11th 2019

Harsha Ranganath, MD, discusses the current and future treatment of patients with nonmetastatic castration-resistant prostate cancer.

Radiation Oncologist Reflects on Traditional Treatment Modalities in Prostate Cancer

January 10th 2019

Holger L. Gieschen, MD, discusses the role of radiation therapy in prostate cancer and ongoing efforts to further refine this strategy.

Prostate Cancer Mortality Progress Stalls, Prompting Questions About PSA Policies

January 9th 2019

An analysis of prostate cancer trends adjusted for delays in reporting by stage of disease showed that incidence of late-stage disease increased from 2010 to 2014 after a decline in prostate-specific antigen use.

Assessing Risk Stratification Across Pivotal Prostate Cancer Trials

January 8th 2019

Daniel Vaena, MD, discusses the treatment of patients with metastatic castration-naïve disease and nonmetastatic castration-resistant prostate cancer, underscoring the importance of risk stratification in both settings.

Rucaparib Shows Encouraging Responses in BRCA+ mCRPC

January 8th 2019

Josep Piulats, MD, discussed the TRITON2 data and how rucaparib could shift treatment for these biomarker-specific patients with metastatic castration-resistant prostate cancer.